Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury

References

• Binder L. M. Persisting symptoms after mild head injury.: a review of the postconcussive syndrome. Journal of Clincal and Experimental Neuropsychology 1986; 8(4)323–346
   PubMed Web of Science ®Google Scholar
• Ommaya A. K., Gennarelli T. A. Cerebral concussion and traumatic unconsciousness.: correlation of experimental and clinical observations on blunt head injuries. Brain 1974; 97: 633–654
   PubMed Web of Science ®Google Scholar
• Holbourn A. H. S. Mechanics of head injuries. Lancet 1943; 2: 438–441
   Google Scholar
• Adams J. H., Mitchell D. E., Graham D. K., et al. Diffuse brain damage of immediate impact type. Brain 1977; 100: 489–502
   PubMed Web of Science ®Google Scholar
• Cope D. N. The pharmacology of attention and memory. Journal of Head Trauma Rehabilitation 1986; 1(3)34–42
   Google Scholar
• Evans R. W., Gualtieri C. T., Patterson D. Treatment of chronic closed head injury with psychostimulant drugs.: a controlled case study and an appropriate evaluation procedure. Journal of Nervous and Mental Diseases 1987; 175(2)106–110
   PubMed Web of Science ®Google Scholar
• Gualtieri C. T., Schroeder S. R., Keppel J. M. Mental retardation. Psychiatric Treatment Manual. American Psychiatric Press, Washington, DC. 1988, (in press)
   Google Scholar
• Gualtieri C. T. Imipramine and children.: a review and some speculations about the mechanisms of drug action. Diseases of the Nervous Systems 1977; 38: 368–375
   PubMedGoogle Scholar
• Evans R. W., Gualtieri C. T. Carbamazepine.: a neuropsychological and psychiatric profile. Clinical Neuropharmacology 1985; 8: 221–241
   PubMed Web of Science ®Google Scholar
• Gualtieri C. T., Hicks R. E. Stimulants and Neuroleptics in Hyperactive Children (letter). Journal of the American Academy of Child Psychiatry 1985; 24(3)363–364
   PubMedGoogle Scholar
• van Woerkom T. C. A.M., Teclken A. W., Mindenhoud J. M. “Difference in neurotransmitter metabolism in frontotemporal-lobe contusion and diffuse cerebral contusion”. Lancet 1977; 812–813, 9 April.
   PubMed Web of Science ®Google Scholar
• Vecht C. J., van Woerkom T. C. A. M., Teelken A. W., et al. Homovanillic acid and 5-hydroxyindoleacetic acid cerebrospinal fluid levels. Archives of Neurology 1975; 32: 792–797
   PubMedGoogle Scholar
• Bareggi S. R., Porta M., Selenati A., et al. Homovanillic acid and 5-hydroxyindole-acetic acid in the CSF of patients after a severe head injury. I. Lumbar CSF concentration in chronic brain post-traumatic syndromes. European Neurology 1975; 13: 528–544
   PubMedGoogle Scholar
• Feeny D. M., Gonzalez A., Law W. A. Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science 1982; 217: 855–857
   PubMed Web of Science ®Google Scholar
• Kasumatsu J., Pettigrew J. D. Preservation of bioncularity after monoculor deprivation in the striate cortex of kittens treated with 6-hydroxydopamine. Journal of Comparative Neurology 1979; 185: 139–162
   PubMed Web of Science ®Google Scholar
• Kasamatusu T., Pettigrew J. D., Ary M. Cortical recovery from effects on monocular deprivation.: acceleration with norepinephrine and suppression with 6-hydroxydopamine. Journal of Neurophysiology 1981; 45(2)139–162
   Web of Science ®Google Scholar
• Faden A. I. Neuropeptides and central nervous system injury.: clinical implications. Archives of Neurology 1986; 43: 501–503
   PubMedGoogle Scholar
• Baskin D. S., Hosobuchi Y. Naloxone reversal of ischaemic neurological deficits in man. Lancet 1981; 2: 272
   PubMed Web of Science ®Google Scholar
• Symons I. E., Emson P. C., Farman J. V. Endogenous opioid poisoning?. British Medical Journal 1982; 284(6113)469–470
   PubMedGoogle Scholar
• Evans R. W., Gualtieri C. T. Proceedings New developments in pediatric psychopharmacology.: psychostimulants and alternative drugs. Annual CPRI Symposium, (in press)
   Google Scholar
• Orlosky M. J. The Klein-Levin syndrome.: a review. Psychosomatics 1982; 23(6)609–617
   PubMed Web of Science ®Google Scholar
• Evans R. W., Gualtieri C. T., Amara I. Methylphenidate and memory.: dissociated effects in hyperactive children. Psychopharmacology 1986; 90(2)211–216
   PubMed Web of Science ®Google Scholar
• Golinko B. E., Rennick P. M., Lewis R. F. Predicting stimulant effectiveness in hyperactive children with a repeatable neuropsychological battery.: a preliminary study. Prog. Neuro-Psychopharmacol 1981; 5: 65–68
   Google Scholar
• Gualtieri C. T., Hicks R E., Levitt J., et al. Mehylphenidate and exercise.: additive effects on motor performance, variable effects on the neuroendocrine response. Neuropsychobiology 1986; 15: 84–88
   PubMed Web of Science ®Google Scholar
• Novich N. M. Drug abuse and drugs in sports. New York State Journal of Medicine 1973; 73: 2597–2600
   PubMedGoogle Scholar
• Evans R. W., Gualtieri C. T. Stimulant effects in closed head injury patients. International Neuropsychological Society Annual Meeting, Washington, DC, 1987
   Google Scholar
• Gualtieri C. T., Hicks R. E. The neuropharmacology of methylphenidate and a neural substrate of childhood hyperactivity. Psychiatric Clinics of North America, J. Bietchman, 1985; 8: 875–892, (4)
   Google Scholar
• Gualtieri C. T., Wargin W., Kanoy R., et al. Clinical studies of methylphenidate serum levels in children and adults. Journal of the American Academy of Child Psychiatry, 21: 19–26
   PubMedGoogle Scholar
• Wetzel C. D., Squires L. B., Janowsky D. Methylphenidate impairs learning and memory in normal adults. Behavioral and Neural Biology 1981; 31: 413–424
   PubMedGoogle Scholar
• Chandler M., Gualtieri C. T. New psychopharmacology for handicapped people.: stimulants, antidepressants, lithium and propranolol. 1988, Ms submitted
   Google Scholar
• Faden A. I. Opiate antagonists and thyrotropin-releasing hormone. Journal of the American Medical Association 1984; 252: 1452–1454
   Web of Science ®Google Scholar
• Mattes J. A pilot trial of amantadine in hyperactive children. Psychopharmacology Bulletin 1980; 16(3)67–69
   PubMedGoogle Scholar
• Langer D. H., Rapoport J. L., Brown G. L., et al. Behavioural effects of carbidopa-Levodopa in hyperactive boys. Journal of the American Academy of Child Psychiatry 1982; 21: 10–18
   PubMedGoogle Scholar
• Zemektin A., Rapoport J. L., Murphy D. L., et al. Treatment of hyperactive children with monoamine oxidase inhibitors. Archives of General Psychiatry 1985; 42: 962–976
   PubMed Web of Science ®Google Scholar
• Clay T. H., Gualtieri C. T., Gullion C. Bupropion in attention deficit/hyperactivity disorder. Psychopharmacology Bulletin, in press
   Google Scholar
• Dement W. C., Guilleminault C. Sleep disorders.: the state of the art. Hospital Practice 1973; 57–71, November
   Google Scholar
• Sadjapour K., Levine M. J., Bertram K. W. Effects of Sinemet following left occipital lobectomy in early childhood. Annual meeting, International Neuropsychological Society, Houston, Texas, 1984, February
   Google Scholar
• Marotta R. F., Potegal M., Glusman M., et al. Dopamine agonists induce recovery from surgically-induced septal rage. Nature 1977; 269(6)513–515
   PubMed Web of Science ®Google Scholar
• Schniedev H., Cox B. A comparison between amantadine and bromocriptine using the stereotyped behaviour response test (SBR) in the rat. European Journal of Pharmacology 1976; 39: 133–141
   PubMed Web of Science ®Google Scholar
• Gianutsos G., Moore K. E. Differential behavioural and biochemical effects of four dopaminergic agonists. Psychopharmacology 1980; 68: 139–146
   PubMed Web of Science ®Google Scholar
• Johnson A. M., Lowe D. M., Vigouret J. M. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-dopa. British Journal of Pharmacology 1976; 56: 59–68
   PubMed Web of Science ®Google Scholar
• Pearlman C. A. Neuroleptic malignant syndrome. a review of the literature. Journal of Clinical Psychopharmacology 1986; 6: 257–273
   PubMed Web of Science ®Google Scholar
• Landfield P. W., Baskin R. K., Pitler T. A. Brain aging correlates.: retardation by hormonal-pharmacological treatments. Science 1981; 214(30)581–584
   PubMedGoogle Scholar
• Svensson T. H. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants.: L-receptor mediation. Science 1978; 202(8)1089–1091
   PubMedGoogle Scholar
• Richelson E. Tricyclic antidepressants and neurotransmitter receptors. Psychiatric Annals 1979; 9(4)16–31
   Web of Science ®Google Scholar
• Gualtieri C. T., Evans R. W. Motor performance in hyperactive children treated with Imipramine, (submitted)
   Google Scholar
• Jackson R. D., Corrigan J. D., Arnett J. A. Amitriptyline for agitation in head injury. Archives of Physical Medicine and Rehabilitation 1985; 66: 180–181
   PubMed Web of Science ®Google Scholar
• Clifford D. B., Rutherford J. L., Hicks F. G., et al. Acute effects of antidepressants on hippocoampal seizures. Annals of Neurology 1985; 18: 692–697
   PubMed Web of Science ®Google Scholar
• Comfort A. Phenelzine therapy.: the doctor, the patient, and the wine and cheese party. Journal of Operational Psychiatry 1982; 13(1)37–40
   Google Scholar
• Robinson D. S., Nies A., Ravaris C. L., et al. Clinical pharmacology of phenelzine. Archives of General Psychiatry 1978; 35: 629–635
   PubMed Web of Science ®Google Scholar
• Saran A. S. Depression after minor closed head injury.: role of dexamethasone suppression test and antidepressants. Journal of Clinical Psychiatry 1985; 46(8)335–338
   PubMed Web of Science ®Google Scholar
• Scher M., Krieger J., Juergens S. Trazodone and priapism. American Journal of Psychiatry 1983; 140: 1362–1363
   PubMed Web of Science ®Google Scholar
• Gartrell N. Increased libido in women receiving trazodone. American Journal of Psychiatry 1986; 143(6)781–782
   PubMed Web of Science ®Google Scholar
• Brogden R. N., Heel R. C., Speight T. M., et al. Trazodone.: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21(6)401–429
   PubMed Web of Science ®Google Scholar
• Gershon S., Newton R. Lack of anticholinergic side effects with a new antidepressant– trazodone. Journal of Clinical Psychiatry 1980; 41(3)100–104
   PubMed Web of Science ®Google Scholar
• Taylor D. P., Hyslop D. K., Riblet L. A. Trazodone, a new nontricyclic antidepressant without anticholinergic activity. Biochemical Pharmacology, 29(15)2149–2150
   PubMedGoogle Scholar
• Cohen B. M., Harris P. Z., Altesman R. I., et al. Amoxapine.: neuroleptic as well as antidepressant?. American Journal of Psychiatry 1982; 139(9)1165–1167
   PubMed Web of Science ®Google Scholar
• Holliday W., Brasfield K. H., Powers B. Grand mal seizures induced by maprotiline. American Journal of Psychiatry 1982; 139(5)673–674
   PubMed Web of Science ®Google Scholar
• Keaton W., Raskind M. Treatment of depression in the medically ill elderly with methylphenidate. American Journal of Psychiatry 1980; 137: 963–965
   PubMed Web of Science ®Google Scholar
• Heninger G. R., Charney D. S., Sternberg D. E. Lithium carbonate augmentation of antidepressant treatment.: an effective prescription for treatment-refractory depression. Archives of General Psychiatry 1983; 40: 1335–1342
   PubMed Web of Science ®Google Scholar
• Gerbino L., Oleshansky M., Gershon S. I. Clinical use and mode of action of lithium. Psychopharmacology.: A Generation of Progress, M. A. Lipton, A. DiMascio, K. F. Killiam. Raven Press, New York 1978; 1261–1275
   Google Scholar
• Cade J. F. J. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 36: 349–352
   Web of Science ®Google Scholar
• Jenner F. A. Lithium and the question of kidney damage. Archives of General Psychiatry 1979; 36: 888–890
   PubMed Web of Science ®Google Scholar
• Reisberg B., Gershon S. Side effects associated with lithium therapy. Archives of General Psychiatry 1979; 36: 879–887
   PubMed Web of Science ®Google Scholar
• Henry G. M., Weingartner H., Murphy D. L. Influence of affective states and psychoactive drugs on verbal learning and memory. American Journal of Psychiatry 1973; 130: 966–971
   PubMed Web of Science ®Google Scholar
• Judd L. L., Hubbard B., Janowsky D. S., et al. The effect of lithium carbonate on the cognitive functions of normal subjects. Archives of General Psychiatry 1977; 34: 355–357
   PubMed Web of Science ®Google Scholar
• Friedman M. J., Culver C. M., Ferrell R. B. On the safety of long-term treatment with lithium. American Journal of Psychiatry 1977; 134: 1123–1126
   PubMed Web of Science ®Google Scholar
• Kusumo K. S., Vaugn M. Effect of lithium salts on memory. British Journal of Psychiatry 1977; 131: 453–457
   PubMed Web of Science ®Google Scholar
• Christodoulo G. N., Kokkevi A., Lykouras E. P. Effects of lithium on memory. American Journal of Psychiatry 1981; 138: 847–848
   PubMed Web of Science ®Google Scholar
• Platt J. E., Campbell M., Green M. H. Effects of lithium carbonate and haloperidol or cognition in aggressive hospitalized school-age children. Journal of Clinical Psychopharmacology 1981; 1: 8–13
   PubMed Web of Science ®Google Scholar
• Brumback R. A., Weinberg W. A., Herjanic B. L. Epileptiform activity in the electroencephalogram induced by lithium carbonate. Pediatrics 1975; 56: 831–834
   PubMed Web of Science ®Google Scholar
• Haas J. F., Cope D. N. Neuropharmacologic management of behavior sequelae in head injury.: a case report. Archives of Physical Medicine and Rehabilitation 1985; 66: 472–474
   PubMed Web of Science ®Google Scholar
• Hale M. S., Donaldson J. O. Lithium carbonate in the treatment of organic brain syndrome. Journal of Nervous and Mental Disease 1982; 170: 362–365
   PubMed Web of Science ®Google Scholar
• Levine L. S., Glen M. B., Wroblewski B., et al. Use of lithium carbonate and comprehensive behavioral treatment in two severely brain-injured patients. Paper presented at San Jose Head Injury Conference. 1986
   Google Scholar
• Rosenbaum A. H., Barry M. J. Positive therapeutic response to lithium in hypomania secondary to organic brain syndrome. American Journal of Psychiatry 1975; 132(10)1072–1073
   PubMed Web of Science ®Google Scholar
• Chavany J. A. Role des causes occasionelles dans le determinisime du ramolissement cerebral (Reflections therapeutiques a le propos). Pratique ete Medecin Francaise 1928; 7: 285–295
   Google Scholar
• Luria A., Naydin V., Tsvetkova L., . Restoration of higher cortical function following local brain damage. Handbook of Clinical Neurology, R. J. Vinkin, G. W. Bruyn, et al. North Holland, Amsterdam 1968; 368–433
   Google Scholar
• Ward A. A., Kennard M. A. Effect of cholinergic drugs on recovery of function following lesions of the central nervous system in monkeys. Yale Journal of Biology and Medicine 1942; 15: 189–228
   PubMedGoogle Scholar
• Coyle J. T., Price D. L., DeLong M. R. Alzheimer's disease.: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190
   PubMed Web of Science ®Google Scholar
• McLean A., Stanton K., Cardenas D. The use of oral physostigmine to improve memory after brain injury. Annual meeting, National Head Injury Foundation, Chicago, 1986, November
   Google Scholar
• Bartus R. T., Dean R. L., Fisher S. K. Cholinergic treatment for age-related memory disturbances.: dead or barely coming of age?. Treatment Development Strategies for Alzheimer's Disease, T. Crook, R. T. Bratus, S. Ferris, S. Gershon. Mark Powley, Madison, Connecticut 1986; 421–450
   Google Scholar
• Jorm A. F. Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease.: a meta-analysis of the literature. Australian and New Zealand Journal of Psychiatry 1986; 20: 237–240
   PubMed Web of Science ®Google Scholar
• Catsman-Berrevoets E. C., Van Harskamp F., Appelhof A. Beneficial effects of physostigmine on clinical amnesic behaviour and neuropsychological Test Results in a Patient with a pest-encephalitic amnesic syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 1986; 49: 1088–89
   PubMed Web of Science ®Google Scholar
• Summers W. K., Majovsky L. V., Marsh G. M., et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New England Journal of Medicine 1986; 315(20)1241–1287
   PubMed Web of Science ®Google Scholar
• Harbaugh R. E., Roverts D. W., Coombs D. W., et al. Preliminary report.: Intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 1984; 15(4)514–518
   PubMed Web of Science ®Google Scholar
• Ittl T. M., Soldatos C. Epileptogenic side effects of psychotropic drugs. Journal of the American Medical Association 1980; 244(13)1460–1463
   Web of Science ®Google Scholar
• Gualtieri C. T., Patterson D. R. Neuroleptic-induced tics in two hyperactive children. American Journal of Psychiatry 1986; 143: 1176–1177
   PubMed Web of Science ®Google Scholar
• Johnson F. N. Psychoactive drugs and stimulus analysis.: III. Adjustment of behavioral measures for drug-induced memory effects and state dependence.: the case of chlorpromazine. International Journal of Neuroscience 1983; 20: 25–32
   PubMed Web of Science ®Google Scholar
• Oliver A. P., Luchins D. J., Wyatt R. J. Neuroleptic-induced seizures.: an in vitro technique for assessing relative risk. Archives of General Psychiatry 1982; 39: 206–209
   PubMed Web of Science ®Google Scholar
• Wise R. A. Neuroleptics and operant behavior.: the anhedonia hypothesis. Behavioral and Brain Sciences 1982; 5: 39–87
   Web of Science ®Google Scholar
• Caine E. D., Pollnsky R. J. Haloperidol-induced dysphoria in patients with Tourette syndrome. American Journal of Psychiatry 1979; 136(9)1216–1217
   PubMed Web of Science ®Google Scholar
• Killian G. A., Holzman P. S., Davis J. M., et al. Effects of psychotropic medication on selected cognitive and perceptual measures. Journal of Abnormal Psychology 1984; 93(1)58–70
   PubMed Web of Science ®Google Scholar
• Kane J. M., Smith J. M. Tardive dyskinesia, prevalence and risk factors. Archives of General Psychiatry 1982; 39: 473–481
   PubMed Web of Science ®Google Scholar
• Annegers J. F., Grabow J. D., Groover R. V. Seizures after head trauma.: a population study. Neurology 1980; 30: 683–689
   PubMed Web of Science ®Google Scholar
• Salazar A. M., Jabbari B., Vance S. C., et al. Epilepsy after penetrating head injury. I. Clinical correlates.: a report of the Vietnam Head Injury Study. Neurology 1985; 35(10)1406–1414
   PubMed Web of Science ®Google Scholar
• Wada J. A. Pharmacologic prophylaxis in the kindling model of epilepsy. Archives of Neurology 1977; 34: 389–395
   PubMed Web of Science ®Google Scholar
• Taylor D. C. Factors influencing the ocurrence of schizophrenia-like psychosis in patients with temporal lobe epilepsy. Psychological Medicine 1975; 5: 249–254
   PubMed Web of Science ®Google Scholar
• Huf R., Schain R. J. Long-term experiences with carbamazepine in children with seizures. Journal of Pediatrics 1981; 97: 310–312
   Web of Science ®Google Scholar
• Snead O. C., Hosey L. C. Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine 1985; 313: 916–921
   PubMed Web of Science ®Google Scholar
• Gardner D. L., Cowdry R. W. Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology 1986; 6(4)236–239
   PubMed Web of Science ®Google Scholar
• Emrich H., von Zerssen D., Kissling W., et al. Therapeutic effects of sodium valproate in mania. American Journal of Psychiatry 1981; 138: 2
   Web of Science ®Google Scholar
• Linnoila M., Buitoni M., Hietal O. The effect of sodium valproate on tardiw dyskinesia. British Journal of Psychiatry 1976; 129: 114–119
   PubMed Web of Science ®Google Scholar
• Lautin A., Angrist B., Stanley M., et al. Sodium valproate in schizophrenia.: some biochemical correlates. British Journal of Psychiatry 1980; 137: 240–244
   PubMed Web of Science ®Google Scholar
• Reisberg B., London E., Ferris S. H., et al. Novel pharmacologic approaches to the trcanm i it of senile dementia of the Alzheimer's type. Psychopharmacology Bulletin 1983; 19: 220–225
   PubMedGoogle Scholar
• Haigh D., Forsyth W. I. The treatment of childhood epilepsy with sodium valproate. Developmental Medicine and Child Neurology 1975; 17: 743–748
   PubMed Web of Science ®Google Scholar
• Jeavons P. M., Clarke J. E. Sodium valproate in the treatment of epilepsy. British Medical Journal 1974; 2: 584–586
   PubMedGoogle Scholar
• Volzke E., Doose H. Dipropylacetate in the treatment of epilepsy. Epilepsia 1973; 14: 185–193
   PubMed Web of Science ®Google Scholar
• Caille E. J. Effects of treatment with dipropylacetamide on vigilance, perception, decisionmaking capacities and sleep of young normal adults. Psychological Medicine, 6: 791–796
   Google Scholar
• Thompson P. J., Trimble M. R. Sodium valproate and cognitive functioning in normal volunteers. British Journal of Clinical Pharmacology 1981; 12: 819–824
   PubMed Web of Science ®Google Scholar
• Lewis J. R. Valproic acid (depakene).: a new anticonvulsant agent. Journal of the American Medical Association 1978; 240: 2190–2192
   Web of Science ®Google Scholar
• Granville-Grossman K. L., Turner P. The effect of propranolol on anxiety. Lancet 1966; 1: 788–790
   PubMed Web of Science ®Google Scholar
• Jefferson J. W. Beta-adrenergic receptor blocking drugs in psychiatry. Archives of General Psychiatry 1974; 31: 681–691
   PubMed Web of Science ®Google Scholar
• Noyes R., Kathol R., Claney J. Antianxiety effects of propranolol.: a review of clinical studies. Anxiety- New Research and Changing Concepts, D. F. Klein, J. Rabkin. Raven Press, New York 1981; 81–93
   Google Scholar
• Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. British Journal of Psychiatry 1969; 115: 1411–1412
   PubMed Web of Science ®Google Scholar
• Tyrer P. J., Lader M. H. Response to propranolol and diazepam in somatic and psychic anxiety. British Medical Journal 1974; 2: 14–16
   PubMed Web of Science ®Google Scholar
• Atsom A., Blum I., Moaz B. The short-term effects of adrenergic blocking agents in a small group of psychotic patients.: preliminary clinical observations. Psychiatrica, Neurologia, Neurochirurgia 1971; 74: 251–258
   Google Scholar
• Atsmon A., Blum I., Steiner M. Further studies with propranolol in psychotic patients. Psychopharmacologia 1972; 27: 249–254
   PubMed Web of Science ®Google Scholar
• Lindstrom L. H., Persseon E. Propranolol in chronic schizophrenia.: a controlled study in neuroleptic-treated patients. British Journal of Psychiatry 1980; 137: 126–130
   PubMed Web of Science ®Google Scholar
• Sheppard G. P. High-dose propranolol in schizophrenia. British Journal of Psychiatry 1979; 134: 470–476
   PubMed Web of Science ®Google Scholar
• Peet M., Middlemiss D. N., Yates R. A. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet 1980; 2: 8–9
   Web of Science ®Google Scholar
• Bacher N. M., Lewis H. A. Low-dose propranolol in tardive dyskinesia. American Journal of Psychiatry 1980; 137: 495–597
   PubMed Web of Science ®Google Scholar
• Tyrer P., Rutherford D., Huggerr T. Benzodiazepine withdrawal symptoms and propranolol. Lancet, 1: 520–522
   PubMed Web of Science ®Google Scholar
• Kales A., Soldatos C R., Cadieux R. Propranolol in the treatment of narcolepsy. Annals of Internal Medicine 1979; 91: 741–743
   PubMed Web of Science ®Google Scholar
• Ahmad S. Phantom limb pain and propranolol. British Medical Journal 1979; 1: 415
   PubMed Web of Science ®Google Scholar
• Elliott F. A. The neurology of explosive rage. Practitioner 1976; 217: 51–60
   PubMedGoogle Scholar
• Elliott F. A. Propranolol for the control of the belligerent behavior following actute brain damage. Annals of Neurology 1977; 489–491
   PubMed Web of Science ®Google Scholar
• Schreier H. A. Use of propranolol in trie treatment of post-encephalitic psychosis. American Journal of Psychiatry 1979; 136: 840–841
   PubMed Web of Science ®Google Scholar
• Yufodfsky S., Williams D., Gorman J. Propranolol in the treatment of patients with chronic brain syndrome. American Journal of Psychiatry 1981; 138: 218–330
   PubMed Web of Science ®Google Scholar
• Mansheim P. Treatment with propranolol of the behavioral sequelae of brain damage. Journal of Clinical Psychiatry 1981; 42: 132
   PubMed Web of Science ®Google Scholar
• Petrie W. M., Ban T. A. Propranolol in organic agitation. Lancet 1981; 1(8215)324
   PubMed Web of Science ®Google Scholar
• Williams D. T., Mehl R., Yudofsky S., Adams D., Roseman B. The Effect of Propranalol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. Journal of American Academy of Child Psychiatry 1982; 21: 129–135
   PubMedGoogle Scholar
• Snyder S. H., Reynolds I. J. Calcium-antagonist drugs.: receptor interactions that clarify therapeutic effects. New England Journal of Medicine 1985; 313(16)995–1001
   PubMed Web of Science ®Google Scholar
• Greenberg D. A. Calcium channel antagonists and the treatment of migraine. Clinical Neuropharmacology 1986; 9(4)311–328
   PubMed Web of Science ®Google Scholar
• Rodenheffer R. J., Rommer J. A., Wigley F., et al. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. New England Journal of Medicine 1983; 308(15)880–884
   PubMed Web of Science ®Google Scholar
• Giannini A. J., Houser W. L., Louiselle R. H., et al. Antimanic effects of verapamil. American Journal of Psychiatry 1984; 141: 1602–1603
   PubMed Web of Science ®Google Scholar
• Dubovsky S. L. Calcium antagonists.: a new class of psychiatric drugs?. Psychiatric Annals 1986; 16: 724–728
   Web of Science ®Google Scholar
• Gitlin M. J., Weiss J. Verapamil as maintenance treatment in bipolar illness.: a case report. Journal of Clinical Psychopharmacology 1984; 4(6)341–343
   PubMed Web of Science ®Google Scholar
• Hoschl C. Verapamil for depression?. American Journal of Psychiatry 1983; 140(8)1100
   PubMed Web of Science ®Google Scholar
• Berg R. A case of Tourettes syndrome treated with nifedipine. Acta Psychiatrica Scandinavica 1985; 72: 400–401
   PubMed Web of Science ®Google Scholar
• Walsh T. L., Lavenstein B., Licamele W. L., et al. Calcium antagonists in the treatment of Tourette's disorder. American Journal of Psychiatry 1986; 143(11)1467–1468
   PubMed Web of Science ®Google Scholar
• Childs A. Naltrexone in organic bulimia. 1986, Preliminary report, unpublished
   Google Scholar
• Simeon J. G., Volauka J., Trites R., et al. Electroencephalographic correlates in children with learning disorders treated with piracetam. Psychopharmacology Bulletin 1983; 19: 716–720
   Web of Science ®Google Scholar
• Dimond S. J., Brouwers E. Y. M. Increase in power of human memory in normal man through use of drugs. Psychopharmacology 1976; 49: 307–309
   PubMed Web of Science ®Google Scholar
• Wilsher C., Melewski J. Effect of piracetam on dyslexics' verbal conceptualizing ability. Psychopharmacology Bulletin 1983; 19: 3–4
   PubMed Web of Science ®Google Scholar
• Smith R. C., Vroutis G., Johnson R., et al. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacology Bulletin, 20: 542–545
   PubMedGoogle Scholar
• Helfgott E., Rudel R. G., Krieger J. Effect of piracetam on the single word and prose reading of dyslexic children. Psychopharmacology Bulletin 1984; 20: 688–690
   PubMed Web of Science ®Google Scholar
• Evans R. W., Gualtieri C. T. Effects of piracetam on verbal memory in dyslexic children.: a negative report. 1986, Unpublished; available from authors
   Google Scholar
• Pugsley T. A., Poschel B. P. H., Downs D. A., et al. Some pharmacological and neurochemical properties of a new cognition activator agent, Pramiracetam (Cl-879). Psychopharmacology Bulletin 1983; 19: 721–726
   Google Scholar
• Poschel B. P. H., Marriott J. G., Gluckman M. I. Pharmacology underlying the cognition-activating properties of pramiracetam (Cl-879). Psychopharmacology Bulletin 1983; 19: 720–721
   Google Scholar
• Branconier R. J., Coif J. D., Dessain E. C., et al. The therapeutic efficacy of pramiracetam in Alzheimer's disease.: preliminary observations. Psychopharmacology Bulletin 1983; 19: 726–730
   Google Scholar
• Izquierdo I., Dias R. D., Souza D. O., et al. Review article.: the role of opioid peptides in memory and learning. Behavioural Brain Research 1980; 1: 451–468
   PubMed Web of Science ®Google Scholar
• Perry R. New pharmacologic treatments for autistic children. Presentation, Annual Meeting Virginia Autism Resource Network. 1986
   Google Scholar
• Herman B. H., Mammond M. K., Egan J., et al. Naltrexone induces dose-dependent decreases in self-injurious behavior. Reprinted from Society for Neuroscience Abstracts 1985; 11, October
   Google Scholar
• Kleber H. D. Clinical aspects of the use of narcotic antagonists.: the state of the art. International Journal of Addiction 1977; 12: 857–61
   PubMed Web of Science ®Google Scholar
• Serby M., Resnick R., Jordan B., et al. Naltrexone and Alzheimer's disease. Progress in Neuropsychology and Biological Psychiatry 1986; 10: 587–590
   PubMed Web of Science ®Google Scholar
• Tariot P. N., Sunderland T., Weingarner H., et al. Low- and high-dose naloxone in dementia of the Alzheimer's type. Psychopharmacology Bulletin 1985; 21: 680–682
   PubMedGoogle Scholar
• Gispen W. H., Isaacson R. L., Spruijt B. M., et al. Melanocortins, neural plasticity and ageing. Progress in Neuropsychology and Biological Psychiatry 1986; 10: 416–426
   Web of Science ®Google Scholar
• Reisberg B., Ferris S. H., Gershon S. An overview of pharmacologic treatment of cognitive decline in the aged. American Journal of Psychiatry 1981; 138(5)593–600
   PubMed Web of Science ®Google Scholar
• De Wied D. Hormonal influences on motivation learning and memory processes. Hospital Practice 1976; 123–131, January
   Google Scholar
• Frederiksen S., d'Elia G., Holsten R. Influence of ACTH-4–10 and unilateral ECT on primary and secondary memory in depressive patients. European Archives of Psychiatry and Neurological Sciences 1985; 234: 291–294
   PubMedGoogle Scholar
• Rigter H., Van Riezen H. Hormones and memory. Psychopharmacology.: A Generation of Progress, M. A. Lipton, A. Dimascib, K. F. Killiam. Raven Press, New York 1978; 677–689
   Google Scholar
• van Wimersam Griedanus Tj. B., Jooles J., De Wied D. Hypothalamic neuropeptides and memory. Acta Neurochirurgica 1985; 75: 99–105
   PubMed Web of Science ®Google Scholar
• Jennekens-Schinkel A., Wintzen A. R., Lanser B. K. A clinical trial with desglycinamide arginine vasopressin for the treatment of memory disorders in man. Progress in Neuropsychopharmacology and Biological Psychiatry 1985; 9: 273–284
   PubMed Web of Science ®Google Scholar
• Legros J. J., Gilot P., Seron X., et al. Influence of vasopressin on learning and memory. Lancet 1978; 41–42, 7 January
   PubMed Web of Science ®Google Scholar
• Tinklenberg J. R., Pigache R., Berger P. A., et al. Desglycinamide-9-arginine-8-vasopressin in cognitively impaired patients. Psychopharmacology Bulletin 1982; 18: 202–204
   PubMedGoogle Scholar
• Faden A. I., Jacobs T. P. Effect of TRH analogs on neurologic recovery after experimental spinal trauma. Neurology 1985; 35(9)1331–1334
   PubMed Web of Science ®Google Scholar
• Fukuda N., Yoshiaki S., Nagawav J. Behavioral and EEG alterations with brain stem compression and effect of TRH in chronic cats. Folia Pharmacologicajaponica 1979; 75: 321–331
   PubMed Web of Science ®Google Scholar
• Miyamoto M., Fukuda N., Narumi S., et al. V-butyrolactone-V-carbonyl-histidyl-prolinamide citrate (DN-1417).: a novel TRH analog with potent effects on the central nervous system. Life Sciences 1981; 28: 861–869
   PubMed Web of Science ®Google Scholar
• Hefti F., Weiner W. J. Nerve growth factor and Alzheimer's disease. Annals of Neurology 1986; 20(3)275–281
   PubMed Web of Science ®Google Scholar
• Solomon S., Hotchkiss E., Saravay S. M., et al. Impairment of memory function by antihypertensive medication. Archives if General Psychiatry 1983; 40: 1109–1112
   PubMed Web of Science ®Google Scholar
• Croog S. H., Levine S., Testa M. A., et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 1986; 314: 1657–1664
   PubMed Web of Science ®Google Scholar
• Deicken R. F. Captopril treatment of depression. Biological Psychiatry 1986; 21: 1425–1428
   PubMed Web of Science ®Google Scholar
• Arnsten A. F. T., Goldman-Rakic P. S. Adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985; 230: 1273–1276
   PubMed Web of Science ®Google Scholar
• McEntee W. J., Mair R. G. Memory enhancement in Korsakoff's psychosis by clonidine.: further evidence for a noradrenergic deficit. Annals of Neurology 1980; 7: 466–470
   PubMed Web of Science ®Google Scholar
• Block R. L., Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Biology, Biochemistry and Behavior 1984; 20: 233–241
   PubMed Web of Science ®Google Scholar
• Tinklenberg J. R., Taylor J. L. Assessments of drug effects on human memory functions. Neuropsychology of Memory, L. R. Squires, N. Butters. Guilford Press, New York 1984; 213–223
   Google Scholar
• Romney D. M., Angus W. R. A brief review of the effects of diazepam on memory. Psychopharmacology Bulletin 1984; 20(2)313–316
   PubMedGoogle Scholar
• Lader M. Psychological effects of buspirone. Journal of Linguistic Psychiatry 1982; 43(12-Sec. 2)62–68
   Google Scholar
• Seidel W. F., Cohen S. A., Bliwtse N. G., et al. Buspirone.: an anxiolytic without sedative effect. Psychopharmacology 1985; 87: 371–373
   PubMed Web of Science ®Google Scholar
• Mattilla M. J., Aranko K., Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. Journal of Clinical Psychiatry 1982; 43(12–Sec 2)56–60
   Web of Science ®Google Scholar
• Goa K. L., Ward A. Buspirone.: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114–129
   PubMed Web of Science ®Google Scholar
• Wood P. L., Nair N. P. V., Lal S., et al. Buspirone.: a potential atypical neuroleptic. Life Sciences 1983; 33: 269–273
   PubMed Web of Science ®Google Scholar
• Harrington R. A., Hamilton C. W., Brogden R. N., et al. Drugs 1983; 25: 451–494
   PubMed Web of Science ®Google Scholar
• Albibi R., McCallum R. W. Metoclopramide.: pharmacology and clinical application. Annals of Internal Medicine 1983; 98: 86–95
   PubMed Web of Science ®Google Scholar